Maximal cytoreduction is related to improved disease-free survival in low-grade ovarian serous carcinoma

Abstract

Objective:

To evaluate the factors predicting oncologic outcomes in low-grade ovarian serous carcinoma (LGOSC).

Methods:

Seventy patients with LGOSC were included in the study. According to the residual disease present at the end of the initial cytoreductive surgery (CRS), surgical outcomes are defined as follows: maximal CRS for absence of macroscopic residual tumors, optimal CRS for macroscopic residual tumors with diameters ranging from 0.1 to ⩽1 cm diameter, and suboptimal CRS for macroscopic residual tumors measuring >1 cm in diameter.

Results:

Five-year disease-free survival (DFS) and cancer-specific survival (CSS) were 61% and 83%, respectively. Surgical outcomes were suboptimal in 3 (4.3%) patients, optimal in 8 (11.4%) patients, and maximal in 59 (84.3%) patients. Stage and surgical outcomes were related to DFS (p < 0.05). Compared with maximal CRS, the presence of residual tumors (suboptimal and optimal debulking) was related to threefold increased risk of disease failure (recurrence or progression) (hazard ratio [95% confidence interval] 3.00 [1.27–7.09]; P=0.012). CSS was associated with disease stage alone (P=0.03). Advanced stage was related with lower DFS and CSS.

Conclusions:

Maximal CRS facilitates an improvement in DFS. Achieving no residual disease after the completion of surgery should be a cornerstone of LGOSC management.

Keywords

Serous carcinoma ovarian carcinoma survival surgery

Get full access to this article

View all access options for this article.

References

Stuart

Kitchener

Bacon

et al . 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer 2011; 21: 750–755.

Silverberg

SG.

Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol 2000; 19: 7–15.

Okoye

Euscher

Malpica

Ovarian low-grade serous carcinoma: a clinicopathologic study of 33 cases with primary surgery performed at a single institution. Am J Surg Pathol 2016; 40: 627–635.

Seidman

Vang

Ronnett

et al . Distribution and case-fatality ratios by cell-type for ovarian carcinomas: a 22-year series of 562 patients with uniform current histological classification. Gynecol Oncol 2015; 136: 336–340.

Malpica

Wong

KK.

The molecular pathology of ovarian serous borderline tumors. Ann Oncol 2016; 27 Suppl 1: i16–i19.

Kaldawy

Segev

Lavie

et al . Low-grade serous ovarian cancer: a review. Gynecol Oncol 2016; 143: 433–438.

Ali

Kalloger

Santos

et al . Stage II to IV low-grade serous carcinoma of the ovary is associated with a poor prognosis: a clinicopathologic study of 32 patients from a population-based tumor registry. Int J Gynecol Pathol 2013; 32: 529–535.

Malpica

Deavers

et al . Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 2004; 28: 496–504.

Eisenhauer

Therasse

Bogaerts

et al . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228–247.

10.

Ferlay

Soerjomataram

Dikshit

et al . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359–E386.

11.

Plaxe

SC.

Epidemiology of low-grade serous ovarian cancer. Am J Obstet Gynecol 2008; 198: e451–458; discussion e458–459.

12.

Chen

Jin

et al . A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology. Onco Targets Ther 2014; 7: 1891–1899.

13.

Fader

Java

Ueda

et al . Survival in women with grade 1 serous ovarian carcinoma. Obstet Gynecol 2013; 122: 225–232.

14.

Schlumbrecht

Sun

Wong

et al . Clinicodemographic factors influencing outcomes in patients with low-grade serous ovarian carcinoma. Cancer. 2011; 117: 3741–3749.

15.

Previs

Kilgore

Craven

et al . Obesity is associated with worse overall survival in women with low-grade papillary serous epithelial ovarian cancer. Int J Gynecol Cancer 2014; 24: 670–675.

16.

Gershenson

Bodurka

et al . Impact of age and primary disease site on outcome in women with low-grade serous carcinoma of the ovary or peritoneum: results of a large single-institution registry of a rare tumor. J Clin Oncol 2015; 33: 2675–2682.

17.

Gershenson

Sun

et al . Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol 2006; 108: 361–368.

18.

Grabowski

Harter

Heitz

et al . Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer: an analysis of the AGO Study Group metadatabase. Gynecol Oncol 2016; 140: 457–462.

19.

Schmeler

Sun

Bodurka

et al . Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 2008; 108: 510–514.

20.

Karalok

Ureyen

Tasci

et al . Maximum surgical effort is warranted for recurrent adult granulosa cell tumors of ovary. Tumori 2016; 102: 404–408.

21.

Fader

Bergstrom

Jernigan

et al . Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival? Gynecol Oncol 2017; 147: 85–91.